GenFleet Therapeutics (Shanghai) Inc.
2595.HK
Hong Kong Stock Exchange28.70
HKD
+0.72
- -
ISIN
CNE1000074L2
Return %
Stock
S&P500
1Y
-31.83
24.99
3Y
-31.83
70.19
5Y
-31.83
77.45
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jiong Lan
- Full Time Employees
- 102
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Building 8 Floors 2 Shanghai SH People's Republic of China 201203
- IPO Date
- Sep 19, 2025
- Website
- genfleet.com
- Similar Companies
- Business
- GenFleet Therapeutics (Shanghai) Inc. operates as a clinical-stage biopharmaceutical company focused on first-in-class therapies in oncology and immunology, with additional programs targeting autoimmune and inflammatory diseases. The company maintains a RAS-targeted discovery and development platform that includes selective and pan-RAS inhibitors across diverse molecular modalities, pursuing both single-agent and combination strategies to address solid tumors such as non-small cell lung cancer and pancreatic cancer, as well as cachexia and related conditions. GenFleet advances a diversified pipeline with core and partner-inclusive programs, leveraging translational science, early-phase and clinical development capabilities, and strategic collaborations to accelerate global access to innovative therapies. The company is headquartered in Shanghai, China, and operates with a global vision, pursuing domestic and international development, regulatory approval, and potential commercialization through collaborations and out-licensing arrangements with other biopharma and listed corporate partners. Founding year is not explicitly disclosed in the provided sources, but GenFleet positions itself as a clinical-stage company established to expand its portfolio across oncology and immunology. The latest corporate developments include ongoing clinical progression of its RAS-targeted assets, expansion of its collaboration network through strategic partnerships with global partners, and ongoing efforts to strengthen its commercial and translational capabilities to support eventual global commercialization. GenFleet emphasizes a governance and operational framework aligned with industry standards for quality, regulatory compliance, and manufacturing readiness to support late-stage development and potential product launches. The company maintains core products and services related to RAS-targeted therapeutic discovery, preclinical and clinical development services, translational science, formulation and process development, quality control, and strategic collaborations to enable broader access to its therapeutic candidates. The organization also outlines its intent to broaden its therapeutic scope into pancreatic cancer, NSCLC, and related disease areas, while pursuing licensing and clinical cooperation opportunities with major listed companies worldwide to enhance its reach and development velocity. GenFleet’s activities are positioned to span domestic Chinese operations and international clinical programs, with a focus on innovative molecular entities and modalities designed to address unmet medical needs in oncology and immunology.